Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of syringaresinol in preparation of medicines for treating depression

A technology for syringaresinol and depression, which can be used in drug combinations, active ingredients of heterocyclic compounds, nervous system diseases, etc., and can solve problems such as difficulty in promotion, toxic side effects, and influence on daily life.

Inactive Publication Date: 2019-08-30
THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the clinical effective rate of these drugs is about 60%, and the best curative effect can be achieved only 6 to 8 weeks after taking the drugs, and these drugs will have serious side effects after long-term use, such as maprotiline and mianserin are likely to induce epilepsy There are often gastrointestinal reactions when taking fluoxetine, which brings a lot of pain and inconvenience to patients, greatly affects people's daily life, and many patients are forced to stop treatment. Difficulties remain, leading many patients to turn to botanicals for treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of syringaresinol in preparation of medicines for treating depression
  • Application of syringaresinol in preparation of medicines for treating depression
  • Application of syringaresinol in preparation of medicines for treating depression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The present invention will be further described below in conjunction with the examples, but not as the basis for limiting the present invention.

[0017] Embodiment of the invention

[0018] The specific steps of the antidepressant activity screening scheme of syringaresin mice in the present invention are as follows:

[0019] 1. Grouping and administration of animals

[0020] Kunming mice, 3-4 weeks old, male and female, weighing 20g-25g. The mice were completely randomly divided into 8 groups, 6 groups in total: blank group (no drug given), model group (distilled water), positive control group (imipramine hydrochloride, 15mg / kg), high-dose syringaresin group (10mg / kg), middle dose group (6mg / kg) and low dose group (2mg / kg). Imipramine hydrochloride and syringaresin were suspended and dispersed with 1% CMC-Na aqueous solution respectively. Each mouse (20 g) was orally administered with 0.2 ml, and all animals were orally administered before 10 am every day, once a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an application of syringaresinol in preparation of medicines for treating depression. When concentration of activity-screened syringaresinol is 12.5 [mu]M, the syringaresinol has an obvious protection activity against SH-SY5Y cell injury induced by sodium glutamate, facilitates further pharmacological and clinical research, and creates conditions for developing themedicines for treating depression.

Description

technical field [0001] The invention relates to the application of syringaresin, in particular to the application of syringaresin in preparing medicine for treating depression. Background technique [0002] Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system and are mainly manifested by sensory, motor, consciousness, and autonomic dysfunction, such as Alzheimer's disease, Parkinson's disease, depression, etc. It has brought great influence to patients' life and work. Among them, depression is a group of chronic syndromes with high recurrence rate and serious harm to human physical and mental health. At present, Western medicine for the treatment of depression mainly focuses on the first-generation tricyclic depressants and monoamine oxidase inhibitors and the second-generation serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, such as fluoxetine, venlafaxine,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/34A61P25/24
CPCA61K31/34A61P25/24
Inventor 杨礼寿杨小生严秋霞李艳梅范艳华杨娟
Owner THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com